REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY

被引：0

作者：

Song, J. ^{[1
,2
]}

Anjohrin, S. ^{[3
]}

Abe, C. ^{[4
]}

Banefelt, J. ^{[5
]}

Rieem, Dun A. ^{[5
]}

Picker, N. ^{[6
]}

Kromer, D. ^{[7
]}

Fuchs, A. ^{[8
]}

Hahn, P. ^{[9
]}

Welby, S. ^{[10
]}

机构：

[1] UCB Pharma, Brussels, Belgium

[2] Karolinska Inst, Stockholm, Sweden

[3] UCB Pharma, Brussels, Belgium

[4] Karolinska Inst & Quantify Res, Stockholm, Sweden

[5] Quantify Res, Stockholm, Sweden

[6] Cytel, Wismar, Germany

[7] Cytel, Berlin, Germany

[8] AOK PLUS, Dresden, Germany

[9] Inst Pharmakookonomie & Arzneimittell IPAM, Wismar, Germany

[10] UCB Pharma, Anderlecht, Belgium

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

HSD60

引用

页码：S305 / S305

页数：1

共 50 条

[1] REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN GERMANY
Anjohrin, S.
Song, J.
Abe, C.
Banefelt, J.
Dun, Rieem A.
Picker, N.
Kromer, D.
Fuchs, A.
Hahn, P.
Welby, S.
VALUE IN HEALTH, 2023, 26 (12) : S300 - S300
[2] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
Guajardo-Aldaco, Andrea L.
Galarza-Delgado, Dionicio A.
Azpiri-Lopez, Jose R.
Colunga-Pedraza, Iris J.
Cardenas-de la Garza, Jesus A.
Arvizu-Rivera, Rosa I.
Elizondo-Benitez, Maria F.
Gonzalez-Gonzalez, Valeria
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[3] Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rosenberg, Vered
Amital, Howard
Chodick, Gabriel
Faccin, Freddy
Gendelman, Omer
DRUGS & AGING, 2024, 41 (08) : 685 - 697
[4] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Choy, Ernest
Aletaha, Daniel
Behrens, Frank
Finckh, Axel
Gomez-Reino, Juan
Gottenberg, Jacques-Eric
Schuch, Florian
Rubbert-Roth, Andrea
RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
[5] EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease, P. J.
Lertratanakul, A.
Strober, B.
Tsuji, S.
Richette, P.
Lovan, C.
Feng, D.
Anderson, J.
Van den Bosch, F.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 788 - 789
[6] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
Mease, Philip
Lertratanakul, Apinya
Strober, Bruce
Tsuji, Shigeyoshi
Richette, Pascal
Lovan, Charlie
Feng, Dai
Anderson, Jaclyn K.
Van den Bosch, Filip
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[7] Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Jin, Yinzhu
Liu, Jun
Desai, Rishi
Kim, Seoyoung
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1428 - 1429
[8] BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: A REAL-WORLD COHORT OF 439 PATIENTS
Letarouilly, J-G
Salmon, J. -H.
Coquerelle, P.
Goeb, V.
Guyot, M. -H.
Houvenagel, E.
Maury, F.
Marguerie, L.
Morel, G.
Baudens, G.
Solau-Gervais, E.
Ramdane, N.
Flipo, R. -M.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 373 - 373
[9] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
Xerxes Pundole
Natalia V. Zamora
Harish Siddhanamatha
Heather Lin
Jean Tayar
Leung Cheuk Hong
Liang Li
Maria E. Suarez-Almazor
Clinical Rheumatology, 2020, 39 : 787 - 794
[10] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
Pundole, Xerxes
Zamora, Natalia V.
Siddhanamatha, Harish
Lin, Heather
Tayar, Jean
Hong, Leung Cheuk
Li, Liang
Suarez-Almazor, Maria E.
CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794

← 1 2 3 4 5 →